Multimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers
- 1Department of Nuclear Medicine, School of Medicine, Philipps-University Marburg, 35043 Marburg, Germany
- 2Department of Urology, School of Medicine, Philipps-University Marburg, 35043 Marburg, Germany
- 3Department of Nuclear Medicine, University Hospital OWL, Evangelical Hospital Bethel, 33617 Bielefeld, Germany
Abstract
This retrospective analysis interrogates the value of a multimodal biomarker paradigm to characterize molecular and clinical responses to [225Ac]Ac-PSMA-617-targeted α-therapy (TAT) in cohorts of heavily pretreated metastatic castration-resistant prostate cancer patients who had shown limited benefit from prior [177Lu]Lu-PSMA-617. By integrating quantitative PSMA-PET/CT metrics—notably total tumor volume (TTV) and lesion SUV indices—with longitudinal PSA kinetics, routine hematologic and biochemical markers, and semiquantitative assessment of salivary gland uptake, we sought to delineate treatment effect, organ-specific off-target impact, and prognostic biomarker signatures. In twelve patients receiving 2–6 cycles of therapy (median activity 8 MBq), biochemical responses were frequent: 8/12 experienced PSA declines and 5/12 achieved ≥50% reduction. Concordant molecular responses were observed on PSMA-PET, with SUVpeak-based partial response in 7/12, stable disease in 3/12, and progressive disease in 2/12 of the target lesions. Qualitative concordance between TTV and PSA response was observed in four illustrative patients; no formal cohort-level concordance analysis was performed. Notably, salivary gland tracer uptake on [68Ga]Ga-PSMA-11 PET/CT decreased after two cycles of [225Ac]Ac-PSMA-617 compared with baseline (SUVmax −63.7%; SUVmean −45.5%). In this exploratory cohort, elevations in PSA, alkaline phosphatase, and LDH measured after two cycles of therapy, along with low hemoglobin, platelet count, and creatinine, were associated with shorter overall survival. Median progression-free survival and overall survival were 27 and 53 weeks, respectively. Collectively, these findings suggest that a combined PSMA-PET TTV–PSA–blood biomarker framework may offer complementary insight alongside PSA alone for characterizing therapeutic response, although its incremental value over PSA was not formally tested in this exploratory cohort; blood-based biomarkers (PSA, ALP) showed the most consistent prognostic association with survival, providing objective measures of both tumor response and collateral tissue impact. Prospective validation in larger, controlled cohorts is warranted to refine biomarker thresholds and guide personalized TAT strategies.
Related
- Integrating PET/CT and correlative biomarkers for prospective evaluation of extramedullary disease in relapsed/refractory B-ALL: implications for CAR T-cell therapy
- A Reduced Digital Motor Assessment using Multimodal Biomarkers in Parkinson's Disease
- Choriocapillaris Dysfunction in Retinal Diseases: Multimodal Imaging Biomarkers, Pathophysiological Insights, and Emerging Clinical Applications
- Choriocapillaris Flow Deficits and Outer Retinal Biomarkers in Early Macular Telangiectasia Type 2: A Multimodal Imaging Study
- Multimodal biomarkers and prediction models for stricturing and penetrating progression in Crohn's disease
BibTeX
@article{ebrahimifard2026multimodal,
title = {{Multimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers}},
author = {Ali Ebrahimifard and Shamim Bagheri and Qi Wang and Azimeh Hojjat Shamami and Pietro Di Fazio and Friederike Eilsberger and Laura Müller and Markus Luster and Damiano Librizzi and Behrooz Hooshyar Yousefi},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209330},
url = {https://www.mdpi.com/1422-0067/27/20/9330},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Multimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers
AU - Ali Ebrahimifard
AU - Shamim Bagheri
AU - Qi Wang
AU - Azimeh Hojjat Shamami
AU - Pietro Di Fazio
AU - Friederike Eilsberger
AU - Laura Müller
AU - Markus Luster
AU - Damiano Librizzi
AU - Behrooz Hooshyar Yousefi
PY - 2026
DA - 2026/10/20
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209330
UR - https://www.mdpi.com/1422-0067/27/20/9330
AB - This retrospective analysis interrogates the value of a multimodal biomarker paradigm to characterize molecular and clinical responses to [225Ac]Ac-PSMA-617-targeted α-therapy (TAT) in cohorts of heavily pretreated metastatic castration-resistant prostate cancer patients who had shown limited benefit from prior [177Lu]Lu-PSMA-617. By integrating quantitative PSMA-PET/CT metrics—notably total tumor volume (TTV) and lesion SUV indices—with longitudinal PSA kinetics, routine hematologic and biochemical markers, and semiquantitative assessment of salivary gland uptake, we sought to delineate treatment effect, organ-specific off-target impact, and prognostic biomarker signatures. In twelve patients receiving 2–6 cycles of therapy (median activity 8 MBq), biochemical responses were frequent: 8/12 experienced PSA declines and 5/12 achieved ≥50% reduction. Concordant molecular responses were observed on PSMA-PET, with SUVpeak-based partial response in 7/12, stable disease in 3/12, and progressive disease in 2/12 of the target lesions. Qualitative concordance between TTV and PSA response was observed in four illustrative patients; no formal cohort-level concordance analysis was performed. Notably, salivary gland tracer uptake on [68Ga]Ga-PSMA-11 PET/CT decreased after two cycles of [225Ac]Ac-PSMA-617 compared with baseline (SUVmax −63.7%; SUVmean −45.5%). In this exploratory cohort, elevations in PSA, alkaline phosphatase, and LDH measured after two cycles of therapy, along with low hemoglobin, platelet count, and creatinine, were associated with shorter overall survival. Median progression-free survival and overall survival were 27 and 53 weeks, respectively. Collectively, these findings suggest that a combined PSMA-PET TTV–PSA–blood biomarker framework may offer complementary insight alongside PSA alone for characterizing therapeutic response, although its incremental value over PSA was not formally tested in this exploratory cohort; blood-based biomarkers (PSA, ALP) showed the most consistent prognostic association with survival, providing objective measures of both tumor response and collateral tissue impact. Prospective validation in larger, controlled cohorts is warranted to refine biomarker thresholds and guide personalized TAT strategies.
SN - 1422-0067
ER -